Sie sind hier: Startseite » Projekte


der RED Oncology

Neben der Beteiligung an zahlreichen nicht-interventionellen Studien und der Teilnahme an Registerprojekten wurden/werden folgende Phase II und Phase III Studien am Institut für onkologische Forschung durchgeführt:

Phase II Studien:


  • Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer

CUP-Belinostat PXD 101-CLN-17

  • An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary


  • Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated Carcinoma of Unknown Primary (CUP)

MX39795 CUPISCO-Studie

  • A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients with Cancer of Unknown Primary Site (CUPISCO)

CheCUP 2nd line CUP

  • Phase II, non randomized, open label, multi center trail evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy

Phase III Studien:

KRK 0504 / ML18147

  • A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination

Morbus Hodgkin Studie

  • HD 17 für intermediäre Stadien, Therapieoptimierungsstudie in der Primärtherapie des intermediären Hodgkin Lymphoms


  • Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional by liposomal vincristine and FDG-PET based reduction of therapy in combination with vitamin D substitution

IMPALA / Erstlinientherapie mit dem Immunmodulat

  • IMPALA-Trial: Evaluation of an immunomodulatory maintenance treatment in patients with metastatic colorectal cancer with tumor reduction during induction treatment - A phase III trial

Wir nutzen Cookies auf unserer Website um diese laufend für Sie zu verbessern. Mehr erfahren